Adjuvant Immunotherapy of Established Murine Renal Cancer by Interleukin 2-stimulated Cytotoxic Lymphocytes

摘要: We have used a transplantable experimental murine renal carcinoma (Renca) to evaluate the adjuvant immunotherapeutic potential of cytotoxic lymphocytes stimulated by in vitro incubation for 24 h with human recombinant interleukin 2 (rIL-2). The Renca tumor model is therapeutically challenging since, following intrarenal implant, it grows progressively local invasion and development spontaneous metastases abdominal lymph nodes, lungs, liver. Therefore, successful treatment requires control both primary tumor, regional invasive growth, systemic metastases. Our studies shown that rIL-2-stimulated efficiently lyse . Further, doxorubicin hydrochloride an active metabolite cyclophosphamide also inhibited growth In vivo administration hydrochloride, or rIL-2 mice bearing established tumors (7-day disease) resulted significant ( P < 0.01) increase short-term survivors (at 45 days), but only 17% cures. However, combination chemoimmunotherapy consisting plus results cure 67% Renca. These demonstrate chemotherapy immunotherapy adoptively transferred can function synergistically carcinoma.